Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACIU NASDAQ:AMLX NASDAQ:IMNM NASDAQ:IOVA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$2.43+2.1%$2.17$1.43▼$3.98$244M1.61127,784 shs172,212 shsAMLXAmylyx Pharmaceuticals$11.65-1.6%$8.64$2.48▼$12.25$1.04B-0.451.83 million shs2.15 million shsIMNMImmunome$9.21-4.9%$9.94$5.15▼$16.73$801.68M1.92999,354 shs5.21 million shsIOVAIovance Biotherapeutics$2.27-6.2%$2.44$1.64▼$12.51$821.41M0.8210.66 million shs8.51 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune0.00%+6.58%+14.08%+24.62%-20.59%AMLXAmylyx Pharmaceuticals0.00%+14.22%+38.53%+111.05%+353.31%IMNMImmunome0.00%-12.45%-7.34%+0.11%-36.31%IOVAIovance Biotherapeutics0.00%-8.84%-7.35%+1.34%-75.72%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$2.43+2.1%$2.17$1.43▼$3.98$244M1.61127,784 shs172,212 shsAMLXAmylyx Pharmaceuticals$11.65-1.6%$8.64$2.48▼$12.25$1.04B-0.451.83 million shs2.15 million shsIMNMImmunome$9.21-4.9%$9.94$5.15▼$16.73$801.68M1.92999,354 shs5.21 million shsIOVAIovance Biotherapeutics$2.27-6.2%$2.44$1.64▼$12.51$821.41M0.8210.66 million shs8.51 million shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune0.00%+6.58%+14.08%+24.62%-20.59%AMLXAmylyx Pharmaceuticals0.00%+14.22%+38.53%+111.05%+353.31%IMNMImmunome0.00%-12.45%-7.34%+0.11%-36.31%IOVAIovance Biotherapeutics0.00%-8.84%-7.35%+1.34%-75.72%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACIUAC Immune 2.67Moderate Buy$10.00311.52% UpsideAMLXAmylyx Pharmaceuticals 3.00Buy$12.255.15% UpsideIMNMImmunome 3.00Buy$22.89148.52% UpsideIOVAIovance Biotherapeutics 2.36Hold$11.90424.23% UpsideCurrent Analyst Ratings BreakdownLatest ACIU, IMNM, AMLX, and IOVA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/9/2025ACIUAC ImmuneZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/8/2025ACIUAC ImmuneBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.009/5/2025IMNMImmunomeCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$26.008/28/2025AMLXAmylyx PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$10.00 ➝ $14.008/25/2025IMNMImmunomeGuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$25.008/22/2025IMNMImmunomeEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$18.008/19/2025IOVAIovance BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.008/12/2025IOVAIovance BiotherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold8/8/2025IOVAIovance BiotherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$18.00 ➝ $14.008/8/2025IOVAIovance BiotherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$25.00 ➝ $20.008/7/2025IMNMImmunomeJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$23.00 ➝ $22.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACIUAC Immune$31.02M7.87N/AN/A$1.29 per share1.88AMLXAmylyx Pharmaceuticals$87.37M11.89N/AN/A$2.40 per share4.85IMNMImmunome$9.04M88.68N/AN/A$2.27 per share4.06IOVAIovance Biotherapeutics$164.07M5.01N/AN/A$2.33 per share0.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACIUAC Immune-$57.83M-$0.58N/AN/AN/A-174.94%-49.35%-23.16%11/4/2025 (Estimated)AMLXAmylyx Pharmaceuticals-$301.74M-$2.50N/AN/AN/AN/A-82.48%-70.15%11/6/2025 (Estimated)IMNMImmunome-$292.96M-$3.08N/AN/AN/A-1,687.08%-76.10%-65.14%11/12/2025 (Estimated)IOVAIovance Biotherapeutics-$372.18M-$1.23N/AN/AN/A-161.44%-52.87%-41.31%11/6/2025 (Estimated)Latest ACIU, IMNM, AMLX, and IOVA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025AMLXAmylyx Pharmaceuticals-$0.44-$0.46-$0.02-$0.46N/AN/A8/7/2025Q2 2025IOVAIovance Biotherapeutics-$0.29-$0.33-$0.04-$0.33$67.14 million$59.95 million8/6/2025Q2 2025IMNMImmunome-$0.52-$0.50+$0.02-$0.50$1.03 million$4.02 million8/5/2025Q2 2025ACIUAC Immune-$0.20-$0.25-$0.05-$0.25$1.98 million$1.65 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACIUAC ImmuneN/AN/AN/AN/AN/AAMLXAmylyx PharmaceuticalsN/AN/AN/AN/AN/AIMNMImmunomeN/AN/AN/AN/AN/AIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACIUAC ImmuneN/A1.331.33AMLXAmylyx PharmaceuticalsN/A8.728.72IMNMImmunomeN/A12.1312.13IOVAIovance BiotherapeuticsN/A3.272.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACIUAC Immune51.36%AMLXAmylyx Pharmaceuticals95.84%IMNMImmunome44.58%IOVAIovance Biotherapeutics77.03%Insider OwnershipCompanyInsider OwnershipACIUAC Immune4.60%AMLXAmylyx Pharmaceuticals12.30%IMNMImmunome7.69%IOVAIovance Biotherapeutics10.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACIUAC Immune140100.41 million95.79 millionOptionableAMLXAmylyx Pharmaceuticals20089.17 million78.20 millionOptionableIMNMImmunome4087.04 million80.35 millionOptionableIOVAIovance Biotherapeutics500361.85 million324.58 millionOptionableACIU, IMNM, AMLX, and IOVA HeadlinesRecent News About These CompaniesAnalysts Set Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Price Target at $11.90September 12 at 2:49 AM | americanbankingnews.comJacobs Levy Equity Management Inc. Takes Position in Iovance Biotherapeutics, Inc. $IOVASeptember 11 at 4:08 AM | marketbeat.comIovance Biotherapeutics, Inc. (NASDAQ:IOVA) Given Consensus Recommendation of "Hold" by BrokeragesSeptember 10, 2025 | marketbeat.comAmerican Century Companies Inc. Decreases Stake in Iovance Biotherapeutics, Inc. $IOVASeptember 9, 2025 | marketbeat.comH.C. Wainwright Keeps Buy Rating on Iovance (IOVA) After Health Canada Authorization NewsSeptember 8, 2025 | insidermonkey.comInvenomic Capital Management LP Invests $18.28 Million in Iovance Biotherapeutics, Inc. $IOVASeptember 7, 2025 | marketbeat.comIovance Stock Faces Triple Threat from Mixed Signals and Earnings MissSeptember 5, 2025 | aktiencheck.deA683 Capital Management LLC Purchases 983,986 Shares of Iovance Biotherapeutics, Inc. $IOVASeptember 4, 2025 | marketbeat.comIovance Biotherapeutics, Inc. $IOVA Shares Acquired by Palo Alto Investors LPSeptember 4, 2025 | marketbeat.comRafferty Asset Management LLC Sells 132,612 Shares of Iovance Biotherapeutics, Inc. $IOVASeptember 3, 2025 | marketbeat.comLong Focus Capital Management LLC Purchases 4,118,055 Shares of Iovance Biotherapeutics, Inc. $IOVASeptember 1, 2025 | marketbeat.comNuveen LLC Takes Position in Iovance Biotherapeutics, Inc. $IOVAAugust 31, 2025 | marketbeat.comOrion Investment Co Buys 116,098 Shares of Iovance Biotherapeutics, Inc. $IOVAAugust 30, 2025 | marketbeat.comCharles Schwab Investment Management Inc. Sells 141,599 Shares of Iovance Biotherapeutics, Inc. $IOVAAugust 30, 2025 | marketbeat.comIovance Biotherapeutics to Present at Upcoming ConferencesAugust 29, 2025 | globenewswire.comIovance: Thin Margins, Dilution Threat Keep Risk SkewedAugust 27, 2025 | seekingalpha.comIovance Biotherapeutics (NASDAQ:IOVA) Shares Gap Down - Here's WhyAugust 27, 2025 | marketbeat.comIovance Biotherapeutics Faces Investor Backlash Over Major Equity OfferingAugust 27, 2025 | aktiencheck.deAIovance Biotherapeutics, Inc. $IOVA Shares Sold by T. Rowe Price Investment Management Inc.August 27, 2025 | marketbeat.comCapital Fund Management S.A. Acquires 409,688 Shares of Iovance Biotherapeutics, Inc. $IOVAAugust 27, 2025 | marketbeat.comIOVA Stock Drops 6% on $350M Common Stock OfferingAugust 26, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeACIU, IMNM, AMLX, and IOVA Company DescriptionsAC Immune NASDAQ:ACIU$2.43 +0.05 (+2.10%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.43 0.00 (0.00%) As of 09/12/2025 06:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Amylyx Pharmaceuticals NASDAQ:AMLX$11.65 -0.19 (-1.60%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$11.66 +0.00 (+0.04%) As of 09/12/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Immunome NASDAQ:IMNM$9.21 -0.47 (-4.86%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$9.32 +0.11 (+1.19%) As of 09/12/2025 06:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.Iovance Biotherapeutics NASDAQ:IOVA$2.27 -0.15 (-6.20%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$2.32 +0.05 (+2.20%) As of 09/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
